PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
17170094-7	2007	The ATRA-induced tube formation was inhibited by coincubation with RAR antagonist LE540/LE135.	LE 135	88-93	retinoic acid receptor alpha	Homo sapiens	67-70
18453568-7	2008	Moreover, LE135, a RA receptor antagonist, blocked the increased expression of CCR9 driven by IL-4-treated MLN-DC.	LE 135	10-15	chemokine (C-C motif) receptor 9	Mus musculus	79-83
18453568-7	2008	Moreover, LE135, a RA receptor antagonist, blocked the increased expression of CCR9 driven by IL-4-treated MLN-DC.	LE 135	10-15	interleukin 4	Mus musculus	94-98
11945126-6	2002	LE135 (46) is a unique antagonist with RARbeta-selectivity.	LE 135	0-5	retinoic acid receptor beta	Homo sapiens	39-46
12882839-10	2003	The RA receptor (RAR) antagonists, LE540 and LE135, but not the retinoic X receptor (RXR) antagonist, PA452, inhibited the effect of RA on Th1/Th2 development.	LE 135	45-50	retinoic acid receptor, alpha	Mus musculus	4-15
12882839-10	2003	The RA receptor (RAR) antagonists, LE540 and LE135, but not the retinoic X receptor (RXR) antagonist, PA452, inhibited the effect of RA on Th1/Th2 development.	LE 135	45-50	retinoic acid receptor, alpha	Mus musculus	17-20
12882839-10	2003	The RA receptor (RAR) antagonists, LE540 and LE135, but not the retinoic X receptor (RXR) antagonist, PA452, inhibited the effect of RA on Th1/Th2 development.	LE 135	45-50	negative elongation factor complex member C/D, Th1l	Mus musculus	139-142
12882839-10	2003	The RA receptor (RAR) antagonists, LE540 and LE135, but not the retinoic X receptor (RXR) antagonist, PA452, inhibited the effect of RA on Th1/Th2 development.	LE 135	45-50	heart and neural crest derivatives expressed 2	Mus musculus	143-146
10336422-9	1999	These results demonstrate that LE135 and LE540 were a novel class of RARbeta-selective antagonists and anti-AP-1 retinoids and should be useful tools for studying the role of retinoids and their receptors.	LE 135	31-36	retinoic acid receptor beta	Homo sapiens	69-76
10336422-3	1999	Both LE135 and LE540 inhibited retinoic acid (RA)-induced transcriptional activation of RARbeta, but not RARalpha, RARgamma or retinoid X receptor alpha (RXRalpha), on a variety of RA response elements.	LE 135	5-10	retinoic acid receptor beta	Homo sapiens	88-95
32278009-5	2020	Our results confirmed this hypothesis because: i) protection of PTC by DIDS was abolished by RAR-beta antagonist LE-135; ii) DIDS increased the expression of RAR-beta in PTC and prevented its decrease in cisplatin-treated PTC but not in cisplatin-treated human cervical adenocarcinoma HeLa cells in which DIDS failed to prevent cisplatin"s toxicity; iii) while RAR-beta expression decreased in cisplatin-treated PTC, RAR-beta over-expression prevented cisplatin"s toxicity.	LE 135	113-119	retinoic acid receptor alpha	Homo sapiens	93-101
10336422-7	1999	Our data showed that LE135 and LE540 strongly repressed 12-O-tetradecanoylphorbol-13-acetate-induced AP-1 activity in the presence of RARbeta and RXRalpha.	LE 135	21-26	retinoic acid receptor beta	Homo sapiens	134-141
10336422-7	1999	Our data showed that LE135 and LE540 strongly repressed 12-O-tetradecanoylphorbol-13-acetate-induced AP-1 activity in the presence of RARbeta and RXRalpha.	LE 135	21-26	retinoid X receptor alpha	Homo sapiens	146-154
35608792-5	2022	Similarly, LE135 (a selective RARbeta antagonist) attenuated AD action, suggesting that AD promotes adipose browning through RARbeta.	LE 135	11-16	retinoic acid receptor, alpha	Mus musculus	30-37
35608792-5	2022	Similarly, LE135 (a selective RARbeta antagonist) attenuated AD action, suggesting that AD promotes adipose browning through RARbeta.	LE 135	11-16	retinoic acid receptor, alpha	Mus musculus	125-132
34001245-16	2021	RARbeta inhibitor Le135 partly blocked the reversal effect of ATRA.	LE 135	18-23	retinoic acid receptor, alpha	Mus musculus	0-7
32278009-5	2020	Our results confirmed this hypothesis because: i) protection of PTC by DIDS was abolished by RAR-beta antagonist LE-135; ii) DIDS increased the expression of RAR-beta in PTC and prevented its decrease in cisplatin-treated PTC but not in cisplatin-treated human cervical adenocarcinoma HeLa cells in which DIDS failed to prevent cisplatin"s toxicity; iii) while RAR-beta expression decreased in cisplatin-treated PTC, RAR-beta over-expression prevented cisplatin"s toxicity.	LE 135	113-119	retinoic acid receptor alpha	Homo sapiens	158-166
32278009-5	2020	Our results confirmed this hypothesis because: i) protection of PTC by DIDS was abolished by RAR-beta antagonist LE-135; ii) DIDS increased the expression of RAR-beta in PTC and prevented its decrease in cisplatin-treated PTC but not in cisplatin-treated human cervical adenocarcinoma HeLa cells in which DIDS failed to prevent cisplatin"s toxicity; iii) while RAR-beta expression decreased in cisplatin-treated PTC, RAR-beta over-expression prevented cisplatin"s toxicity.	LE 135	113-119	retinoic acid receptor alpha	Homo sapiens	158-166
32278009-5	2020	Our results confirmed this hypothesis because: i) protection of PTC by DIDS was abolished by RAR-beta antagonist LE-135; ii) DIDS increased the expression of RAR-beta in PTC and prevented its decrease in cisplatin-treated PTC but not in cisplatin-treated human cervical adenocarcinoma HeLa cells in which DIDS failed to prevent cisplatin"s toxicity; iii) while RAR-beta expression decreased in cisplatin-treated PTC, RAR-beta over-expression prevented cisplatin"s toxicity.	LE 135	113-119	retinoic acid receptor alpha	Homo sapiens	158-166
29926831-10	2018	Interestingly, LE135 treatment also inhibits the normal downregulation of RXRalpha in tail and spinal cord tissues at 21 dpa.	LE 135	15-20	retinoid x receptor, gamma a	Danio rerio	74-82
30461012-6	2019	The rosiglitazone- and ATRA-induced elevation of mRNA level, Mg 2+ influx, and promoter activity of TRPM6 were inhibited by GW-9662, a potent antagonist of peroxisome proliferator-activated receptor (PPAR)gamma, and LE135, a retinoic acid receptor (RAR) antagonist, respectively.	LE 135	216-221	transient receptor potential cation channel, subfamily M, member 6	Rattus norvegicus	100-105
30461012-10	2019	A chromatin immunoprecipitation assay revealed that PPARgamma and RAR bind to the PPRE, which was blocked by GW-9662 and LE135, respectively.	LE 135	121-126	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	52-61
31359396-4	2019	The levels of RARbeta signaling can be modulated using RARbeta agonists (e.g., all-trans retinoic acid) and antagonists (e.g., LE135).	LE 135	127-132	retinoic acid receptor beta	Homo sapiens	14-21
29154149-5	2017	On the other hand, we found that the inhibition of RARbeta with 5muM LE135, together with RA treatment, increased the efficiency of mouse ES cell differentiation into neurons by more than 4-fold as compared to cells treated with RA only.	LE 135	69-74	retinoic acid receptor, beta	Mus musculus	51-58
26967733-10	2016	Western blot assay revealed that RARbeta protein levels were increased significantly in a time-dependent manner in ARPE-19 cells treated with 10-6 mol/l ATRA from 12 h to 72 h, with a marked increase observed at 24 h and 48 h. The upregulation of RARbeta and the ATRA-induced secretion in ARPE-19 cells could be inhibited by the RARbeta antagonist LE135.	LE 135	348-353	retinoic acid receptor beta	Homo sapiens	33-40
21308729-1	2011	The present study aimed to investigate the role of a retinoic acid receptor-beta (RARbeta) inhibitor LE135 on TGF-beta induced chondrogenesis of human bone marrow mesenchymal stem cells (hMSCs).	LE 135	101-106	retinoic acid receptor beta	Homo sapiens	53-80
24308840-3	2014	Here, we demonstrate that LE135 [4-(7,8,9,10-tetrahydro-5,7,7,10,10-pentamethyl-5H-benzo[e]naphtho[2,3-b][1,4]diazepin-13-yl)benzoic acid], a selective antagonist of RARbeta , is a potent activator of the capsaicin (TRPV1) and wasabi (TRPA1) receptors, two critical pain-initiating cation channels.	LE 135	26-31	retinoic acid receptor beta	Homo sapiens	166-173
24308840-3	2014	Here, we demonstrate that LE135 [4-(7,8,9,10-tetrahydro-5,7,7,10,10-pentamethyl-5H-benzo[e]naphtho[2,3-b][1,4]diazepin-13-yl)benzoic acid], a selective antagonist of RARbeta , is a potent activator of the capsaicin (TRPV1) and wasabi (TRPA1) receptors, two critical pain-initiating cation channels.	LE 135	26-31	transient receptor potential cation channel subfamily V member 1	Homo sapiens	216-221
24308840-3	2014	Here, we demonstrate that LE135 [4-(7,8,9,10-tetrahydro-5,7,7,10,10-pentamethyl-5H-benzo[e]naphtho[2,3-b][1,4]diazepin-13-yl)benzoic acid], a selective antagonist of RARbeta , is a potent activator of the capsaicin (TRPV1) and wasabi (TRPA1) receptors, two critical pain-initiating cation channels.	LE 135	26-31	transient receptor potential cation channel subfamily A member 1	Homo sapiens	235-240
24308840-4	2014	EXPERIMENTAL APPROACH: We performed to investigate the excitatory effects of LE135 on TRPV1 and TRPA1 channels expressed in HEK293T cells and in dorsal root ganglia neurons with calcium imaging and patch-clamp recordings.	LE 135	77-82	transient receptor potential cation channel subfamily V member 1	Homo sapiens	86-91
24308840-4	2014	EXPERIMENTAL APPROACH: We performed to investigate the excitatory effects of LE135 on TRPV1 and TRPA1 channels expressed in HEK293T cells and in dorsal root ganglia neurons with calcium imaging and patch-clamp recordings.	LE 135	77-82	transient receptor potential cation channel subfamily A member 1	Homo sapiens	96-101
24308840-5	2014	We also used site-directed mutagenesis of the channels to determine the structural basis of LE135-induced activation of TRPV1 and TRPA1 channels and behavioural testing to examine if pharmacological inhibition and genetic deletion of the channels affected LE135-evoked pain-related behaviours.	LE 135	92-97	transient receptor potential cation channel subfamily V member 1	Homo sapiens	120-125
24308840-5	2014	We also used site-directed mutagenesis of the channels to determine the structural basis of LE135-induced activation of TRPV1 and TRPA1 channels and behavioural testing to examine if pharmacological inhibition and genetic deletion of the channels affected LE135-evoked pain-related behaviours.	LE 135	92-97	transient receptor potential cation channel subfamily A member 1	Homo sapiens	130-135
24308840-6	2014	KEY RESULTS: LE135 activated both the capsaicin receptor (TRPV1) and the allyl isothiocyanate receptor (TRPA1) heterologously expressed in HEK293T cells and endogenously expressed by sensory nociceptors.	LE 135	13-18	transient receptor potential cation channel subfamily V member 1	Homo sapiens	38-56
24308840-6	2014	KEY RESULTS: LE135 activated both the capsaicin receptor (TRPV1) and the allyl isothiocyanate receptor (TRPA1) heterologously expressed in HEK293T cells and endogenously expressed by sensory nociceptors.	LE 135	13-18	transient receptor potential cation channel subfamily V member 1	Homo sapiens	58-63
24308840-6	2014	KEY RESULTS: LE135 activated both the capsaicin receptor (TRPV1) and the allyl isothiocyanate receptor (TRPA1) heterologously expressed in HEK293T cells and endogenously expressed by sensory nociceptors.	LE 135	13-18	transient receptor potential cation channel subfamily A member 1	Homo sapiens	104-109
24308840-7	2014	Mutations disrupting the capsaicin-binding site attenuated LE135 activation of TRPV1 channels and a single mutation (K170R) eliminated TRPA1 activity evoked by LE135.	LE 135	59-64	transient receptor potential cation channel subfamily V member 1	Homo sapiens	79-84
24308840-9	2014	Both TRPV1 and TRPA1 channels were involved in LE135-elicited pain-related responses, as shown by pharmacological and genetic ablation studies.	LE 135	47-52	transient receptor potential cation channel subfamily V member 1	Homo sapiens	5-10
24308840-9	2014	Both TRPV1 and TRPA1 channels were involved in LE135-elicited pain-related responses, as shown by pharmacological and genetic ablation studies.	LE 135	47-52	transient receptor potential cation channel subfamily A member 1	Homo sapiens	15-20
23946634-10	2013	Pretreatment of the HSFs with LE135, an antagonist of retinoic acid receptor beta (RARbeta), abolished the ATRA-induced changes inactivation of ERK 1/2 and JNK.	LE 135	30-35	retinoic acid receptor beta	Homo sapiens	54-81
23946634-10	2013	Pretreatment of the HSFs with LE135, an antagonist of retinoic acid receptor beta (RARbeta), abolished the ATRA-induced changes inactivation of ERK 1/2 and JNK.	LE 135	30-35	retinoic acid receptor beta	Homo sapiens	83-90
23946634-10	2013	Pretreatment of the HSFs with LE135, an antagonist of retinoic acid receptor beta (RARbeta), abolished the ATRA-induced changes inactivation of ERK 1/2 and JNK.	LE 135	30-35	mitogen-activated protein kinase 3	Homo sapiens	144-151
23946634-10	2013	Pretreatment of the HSFs with LE135, an antagonist of retinoic acid receptor beta (RARbeta), abolished the ATRA-induced changes inactivation of ERK 1/2 and JNK.	LE 135	30-35	mitogen-activated protein kinase 8	Homo sapiens	156-159
22052812-6	2011	Treatment with LE135, a RARbeta-selective antagonist, caused a significant inhibition of ependymal outgrowth and a decrease in tail regenerate length.	LE 135	15-20	retinoic acid receptor beta	Homo sapiens	24-31
24851851-1	2014	AIM: Main objective was to investigate whether the synthetic retinoic acid receptor (RAR)-beta antagonist LE135 is able to drive in vitro chondrogenesis of human mesenchymal stromal cells (MSCs) or improve differentiation by suppressing hypertrophic chondrocyte development.	LE 135	106-111	retinoic acid receptor beta	Homo sapiens	85-88
23318218-12	2013	The neuronal differentiation promoting effects of all-trans retinoic acid on mesenchymal stem cells could be inhibited by siRNA silencing of retinoic acid receptor beta and by LE135, an inhibitor of retinoic acid receptor beta.	LE 135	176-181	retinoic acid receptor beta	Homo sapiens	199-226
21763841-14	2011	However, there was no significant difference in the ARM rescue rate between group B and Group C. CONCLUSION: The present study provides evidence that in the hindgut region, RAR selective retinoid antagonist, LE135, could rescue embryos from ARM.	LE 135	208-213	Rab40B, member RAS oncogene family	Mus musculus	173-176
21308729-1	2011	The present study aimed to investigate the role of a retinoic acid receptor-beta (RARbeta) inhibitor LE135 on TGF-beta induced chondrogenesis of human bone marrow mesenchymal stem cells (hMSCs).	LE 135	101-106	retinoic acid receptor beta	Homo sapiens	82-89